Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
Status:
Completed
Trial end date:
2013-08-02
Target enrollment:
Participant gender:
Summary
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise
healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density
(BMD) and serum markers of bone metabolism when compared to transdermal placebo and
abaloparatide injection for 6 months of treatment.